Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topical corticosteroid Rx-to-OTC switch

Executive Summary

Safety data for over-the-counter switches of topical corticosteroid products will be discussed at a joint meeting of FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees on March 24. The committees will focus particularly on the evaluation of the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse events with topical steroids. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit]...





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts